Pityriasis rubra pilaris: treatment with biologics - a new promising therapy?

Dermatology. 2012;224(2):120-5. doi: 10.1159/000337546. Epub 2012 Apr 12.

Abstract

Pityriasis rubra pilaris (PRP) includes a spectrum of rare chronic inflammatory disorders with papulosquamous eruptions of unknown cause. Different etiologies have been proposed such as vitamin A metabolism dysfunction, association with autoimmune disorders, infection or malignancies. However, PRP seems to be a polygenic skin disorder. Classical systemic treatment is empirical and includes retinoids and methotrexate; however, only few series on treatments exist. Recently there has been an increasing number of reports documenting that new biologicals and in particular TNF-α blockers are safe and effective.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adalimumab
  • Adult
  • Anti-Inflammatory Agents / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Biological Products / therapeutic use*
  • Female
  • Humans
  • Male
  • Pityriasis Rubra Pilaris / diagnosis
  • Pityriasis Rubra Pilaris / drug therapy*
  • Pityriasis Rubra Pilaris / pathology
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal, Humanized
  • Biological Products
  • Adalimumab